NetraMark Holdings Inc. Stock price

Equities

AIAI

CA64119M1059

Software

Market Closed - Canadian Securities Exchange 03:58:06 2024-03-28 pm EDT 5-day change 1st Jan Change
0.3 CAD +17.65% Intraday chart for NetraMark Holdings Inc. +7.14% -14.29%
Sales 2022 0.11 0.15 Sales 2023 0.09 0.12 Capitalization 25.18M 34.09M
Net income 2022 -13M -17.6M Net income 2023 -14M -18.95M EV / Sales 2022 111,954,021 x
Net cash position 2022 15.09K 20.43K Net cash position 2023 1.78M 2.41M EV / Sales 2023 262,139,559 x
P/E ratio 2022
-0.9 x
P/E ratio 2023
-1.35 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 86.3%
More Fundamentals * Assessed data
Dynamic Chart
NetraMark Holdings Inc. Signs Contract with Pharmaceutical Company to Deliver Clinical Trial Insights Regarding Efficacy and Placebo Response CI
NetraMark Presenting New Data Showing Ability of its Proprietary NetraAI Clinical Trial Solution in PD Insights MT
NetraMark Holdings Inc. Announces the Presentation of New Data Demonstrating the Ability of its Proprietary NetraAI Clinical Trial Solution CI
NetraMark Holdings Inc. Signs Fourth Contract with Large Biopharmaceutical Company to Enhance Clinical Trial CI
NetraMark Holdings Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Netramark Holdings Inc. Announces Presentations of New Data Demonstrating the Application of Its Netraai Clinical Solution to Data Sets of Less Than 400 Patients CI
NetraMark Holdings Inc. to Present New Data Supporting the Potential of Its Proprietary NetraAI Clinical Trial Solution to De-Risk Clinical Trials CI
NetraMark Holdings Inc. Announces Launch of the NetraAI Lab Offering CI
NetraMark Up 8.6% After Reporting Third Contract With Biopharmaceutical Firm MT
Netramark Holdings Inc. Signs Third Contract with Biopharmaceutical Company CI
NetraMark Holdings Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
NetraMark's Generative AI Discovers Novel Rare Disease Drug Targets and Unique Patient Subpopulations That Could Substantially Improve Clinical Trial Success Rates CI
NetraMark Holdings Inc. Signs Two Contracts with Large Biopharmaceutical Company to Enhance Clinical Trial Insights CI
257,550 Common Share of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2023. CI
30,000 Options of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2023. CI
More news
1 day+17.65%
1 week+7.14%
Current month-3.23%
1 month-1.64%
3 months-14.29%
6 months-21.05%
Current year-14.29%
More quotes
1 week
0.25
Extreme 0.245
0.30
1 month
0.25
Extreme 0.245
0.34
Current year
0.25
Extreme 0.245
0.45
1 year
0.19
Extreme 0.185
0.50
3 years
0.15
Extreme 0.15
3.17
5 years
0.15
Extreme 0.15
3.17
10 years
0.15
Extreme 0.15
3.17
More quotes
Managers TitleAgeSince
Chief Executive Officer - 21-08-23
Founder 48 19-05-07
President - -
Members of the board TitleAgeSince
Chairman 55 21-11-20
Director/Board Member 38 21-03-02
Chief Tech/Sci/R&D Officer - 21-10-17
More insiders
Date Price Change Volume
24-03-28 0.3 +17.65% 203,400
24-03-27 0.255 -5.56% 177,203
24-03-26 0.27 -3.57% 342,400
24-03-22 0.28 0.00% 118,000
24-03-21 0.28 -6.67% 24,214

Delayed Quote Canadian Securities Exchange, March 28, 2024 at 03:58 pm EDT

More quotes
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
More about the company
  1. Stock
  2. Equities
  3. Stock NetraMark Holdings Inc. - Canadian Securities Exchange